Key facts
- Aurora Therapeutics’s last known valuation is $31.0M (Jan 2026).
- It has raised $16.0M; the latest was Seed Round ($16.0M) in Jan 2026.
- Notable investors include Menlo Ventures.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Aurora Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Aurora Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Aurora Therapeutics
Developer of a gene therapeutic platform intended to offer personalized gene editing for rare diseases. The company's platform uses AI to help design its CRISPR-based editors to deliver tailored treatments directly to patients suffering from genetic conditions, enabling patients to get personalised treatment.
- Sector
- Healthcare
- HQ
- Cambridge, MA, United States
- Founded
- 2025
- Website
- auroratherapeutics.com/
- Ownership
- Privately Held (backing)
Aurora Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Aurora Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Aurora Therapeutics in its N-PORT filings yet. We sweep new filings monthly.